Angela Di Paola1, Thomas Lincoln2, Daniel J Skiest2, Maureen Desabrais2, Frederick L Altice3, Sandra A Springer4. 1. Yale University School of Medicine, Department of Internal Medicine, Section of Infectious Diseases, AIDS Program, 135 College St., Suite 323, New Haven, CT 06510, United States. 2. Department of Medicine, Baystate Medical Center, Springfield, MA, United States. 3. Yale University School of Medicine, Department of Internal Medicine, Section of Infectious Diseases, AIDS Program, 135 College St., Suite 323, New Haven, CT 06510, United States; Yale University School of Public Health, Division of Epidemiology of Microbial Diseases, 135 College St., Suite 323, New Haven, CT 06510, United States. 4. Yale University School of Medicine, Department of Internal Medicine, Section of Infectious Diseases, AIDS Program, 135 College St., Suite 323, New Haven, CT 06510, United States. Electronic address: sandra.springer@yale.edu.
Abstract
BACKGROUND: People with opioid dependence and HIV are concentrated within criminal justice settings (CJS). Upon release, however, drug relapse is common and contributes to poor HIV treatment outcomes, increased HIV transmission risk, reincarceration and mortality. Extended-release naltrexone (XR-NTX) is an evidence-based treatment for opioid dependence, yet is not routinely available for CJS populations. METHODS: A randomized, double-blind, placebo-controlled trial of XR-NTX for HIV-infected inmates transitioning from correctional to community settings is underway to assess its impact on HIV and opioid-relapse outcomes. RESULTS: We describe the methods and early acceptability of this trial. In addition we provide protocol details to safely administer XR-NTX near community release and describe logistical implementation issues identified. Study acceptability was modest, with 132 (66%) persons who consented to participate from 199 total referrals. Overall, 79% of the participants had previously received opioid agonist treatment before this incarceration. Thus far, 65 (49%) of those agreeing to participate in the trial have initiated XR-NTX or placebo. Of the 134 referred patients who ultimately did not receive a first injection, the main reasons included a preference for an alternative opioid agonist treatment (37%), being ineligible (32%), not yet released (10%), and lost upon release before receiving their injection (14%). CONCLUSIONS: Study findings should provide high internal validity about HIV and opioid treatment outcomes for HIV-infected prisoners transitioning to the community. The large number of patients who ultimately did not receive the study medication may raise external validity concerns due to XR-NTX acceptability and interest in opioid agonist treatments. CLINICAL TRIAL NUMBER: NCT01246401. Published by Elsevier Inc.
RCT Entities:
BACKGROUND:People with opioid dependence and HIV are concentrated within criminal justice settings (CJS). Upon release, however, drug relapse is common and contributes to poor HIV treatment outcomes, increased HIV transmission risk, reincarceration and mortality. Extended-releasenaltrexone (XR-NTX) is an evidence-based treatment for opioid dependence, yet is not routinely available for CJS populations. METHODS: A randomized, double-blind, placebo-controlled trial of XR-NTX for HIV-infected inmates transitioning from correctional to community settings is underway to assess its impact on HIV and opioid-relapse outcomes. RESULTS: We describe the methods and early acceptability of this trial. In addition we provide protocol details to safely administer XR-NTX near community release and describe logistical implementation issues identified. Study acceptability was modest, with 132 (66%) persons who consented to participate from 199 total referrals. Overall, 79% of the participants had previously received opioid agonist treatment before this incarceration. Thus far, 65 (49%) of those agreeing to participate in the trial have initiated XR-NTX or placebo. Of the 134 referred patients who ultimately did not receive a first injection, the main reasons included a preference for an alternative opioid agonist treatment (37%), being ineligible (32%), not yet released (10%), and lost upon release before receiving their injection (14%). CONCLUSIONS: Study findings should provide high internal validity about HIV and opioid treatment outcomes for HIV-infected prisoners transitioning to the community. The large number of patients who ultimately did not receive the study medication may raise external validity concerns due to XR-NTX acceptability and interest in opioid agonist treatments. CLINICAL TRIAL NUMBER: NCT01246401. Published by Elsevier Inc.
Authors: Jaimie P Meyer; Javier Cepeda; Johnny Wu; Robert L Trestman; Frederick L Altice; Sandra A Springer Journal: JAMA Intern Med Date: 2014-05 Impact factor: 21.873
Authors: Panagiotis Vagenas; Angela Di Paola; Maua Herme; Thomas Lincoln; Daniel J Skiest; Frederick L Altice; Sandra A Springer Journal: J Subst Abuse Treat Date: 2014-03-12
Authors: Raymond F Anton; Stephanie S O'Malley; Domenic A Ciraulo; Ron A Cisler; David Couper; Dennis M Donovan; David R Gastfriend; James D Hosking; Bankole A Johnson; Joseph S LoCastro; Richard Longabaugh; Barbara J Mason; Margaret E Mattson; William R Miller; Helen M Pettinati; Carrie L Randall; Robert Swift; Roger D Weiss; Lauren D Williams; Allen Zweben Journal: JAMA Date: 2006-05-03 Impact factor: 56.272
Authors: Michael S Gordon; Timothy W Kinlock; Robert P Schwartz; Terrence T Fitzgerald; Kevin E O'Grady; Frank J Vocci Journal: Drug Alcohol Depend Date: 2014-06-02 Impact factor: 4.492
Authors: Jeannia J Fu; Maua Herme; Jeffrey A Wickersham; Alexei Zelenev; Amy Althoff; Nickolas D Zaller; Alexander R Bazazi; Ann K Avery; Jeff Porterfield; Alison O Jordan; Dominique Simon-Levine; Martha Lyman; Frederick L Altice Journal: AIDS Behav Date: 2013-10
Authors: Jacques Baillargeon; Thomas P Giordano; Josiah D Rich; Z Helen Wu; Katherine Wells; Brad H Pollock; David P Paar Journal: JAMA Date: 2009-02-25 Impact factor: 56.272
Authors: Elizabeth L C Merrall; Azar Kariminia; Ingrid A Binswanger; Michael S Hobbs; Michael Farrell; John Marsden; Sharon J Hutchinson; Sheila M Bird Journal: Addiction Date: 2010-06-23 Impact factor: 6.526
Authors: Kelsey B Loeliger; Mary L Biggs; Rebekah Young; David W Seal; Curt G Beckwith; Irene Kuo; Michael S Gordon; Frederick L Altice; Lawrence J Ouellet; William E Cunningham; Jeremy D Young; Sandra A Springer Journal: AIDS Behav Date: 2017-10
Authors: Sandra A Springer; Sarah Larney; Zahra Alam-Mehrjerdi; Frederick L Altice; David Metzger; Steven Shoptaw Journal: J Acquir Immune Defic Syndr Date: 2015-06-01 Impact factor: 3.731
Authors: Alan B McGuire; Kristen Gilmore Powell; Peter C Treitler; Karla D Wagner; Krysti P Smith; Nina Cooperman; Lisa Robinson; Jessica Carter; Bradley Ray; Dennis P Watson Journal: J Subst Abuse Treat Date: 2019-06-19
Authors: Maxim Polonsky; Julia Rozanova; Lyuba Azbel; Chethan Bachireddy; Jacob Izenberg; Tetiana Kiriazova; Sergii Dvoryak; Frederick L Altice Journal: AIDS Behav Date: 2016-12
Authors: Ryan D McDonald; Babak Tofighi; Eugene Laska; Keith Goldfeld; Wanda Bonilla; Mara Flannery; Nadina Santana-Correa; Christopher W Johnson; Neil Leibowitz; John Rotrosen; Marc N Gourevitch; Joshua D Lee Journal: Contemp Clin Trials Date: 2016-05-10 Impact factor: 2.226
Authors: Sandra A Springer; Angela Di Paola; Marwan M Azar; Russell Barbour; Breanne E Biondi; Maureen Desabrais; Thomas Lincoln; Daniel J Skiest; Frederick L Altice Journal: J Acquir Immune Defic Syndr Date: 2018-05-01 Impact factor: 3.731